I heard that Mornupiravir was less effective in clinical trials. Is there any effect?

For mornupiravir, an international joint phase III trial, including Japan, has been conducted, and the percentage of participants who were hospitalized or died in an interim analysis was 14.1% in the placebo group, compared with 7.3% in the Mornupiravir group, and the risk reduction rate was 48%.
Either way, consult your doctor about the need to administer the drug and which medication you will receive.

Please refer to the "Examination Report" from the link below for details of the drug approval review, including the results of clinical trials.

• Mornupyravir (sales name: Lagebrio capsule) (external site)
• Caslivimab imdevimab (sale name: ronapleib injection solution set) (outside site)
• Sotrovimab (Sale name: Zebudidy infusion) (external site)